Less is more: A step in the right direction for human papillomavirus (HPV) vaccine implementation

Journal of the National Cancer Institute

Volumn 103, Issue 19, 2011, Pages 1424-1425

  Wheeler, Cosette Marie ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ANTIBODY TITER; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DISEASE SURVEILLANCE; EDITORIAL; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 80054074965     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr354     Document Type: Editorial

References (14)

1. Franceschi S, Denny L, Irwin KL, et al. Eurogin 2010 roadmap on cervical cancer prevention [published online ahead of print March 25, 2001]. Int J Cancer. 2011;128(12):2765-2774. doi:10.1002/ijc.25915.
2. Centers for Disease Control and Prevention (CDC), National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2010, MMWR Morb Mortal Wkly Rep. 2011:117;60:1117-1123.
3. Immunise Australia Program. Human Papillomavirus. http://www.immunise. health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv. Accessed August 1, 2011.
4. Sheridan A and White J for the Department of Health. Annual HPV Vaccine Coverage in England in 2009/2010 [published online ahead of print January 27, 2011]. http://www.dh.gov.uk/en/publicationsandstatistics/publications/ publicationspolicyandguidance/dh-123795. Accessed 26 August 2011
5. Bach PB. Gardasil: from bench, to bedside, to blunder. Lancet. 2010;375(9719):963-964.
6. Desai S, Soldan K, White J, Sheridan A, Gill ON. Human papillomavirus vaccine coverage. Lancet. 2010;376(9738):328-329.
7. Van Damme P, Moiseeva A, Marichev I, et al. Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. BMC Infect Dis. 2010;10:357-364.
8. Dobson S, Dawar M, Kollman T. et al. A two dose HPV vaccine schedule in girls: immunogenicity at 24 months. Poster #691, presented at the 26th International Papillomavirus Conference. July 3-8, 2010, Montreal, Canada.
9. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV 16/18 vaccine. J. Natl Cancer Inst. 2011;103(19):1444-1451.
10. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37):4795-4808.
11. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.
12. Herrero R, Wacholder S, Rodríguez AC. et al. Prevention of persistent HPV infection by a HPV 16-18 vaccine: a community based randomized clinical trial in Guanacaste, Costa Rica. Oral presentation #459, presented at the 26th International Papillomavirus Conference. July 3-8, 2010, Montreal, Canada.
13. ® cross-neutralize HPV 45 pseudovirions. Hum Vaccin. 2007;3(4):109-115. (Pubitemid 47501028)
14. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40(6):564-571. (Pubitemid 46771257)